Journal
FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.943154
Keywords
Advanced breast cancer; hormone receptor; HER2 positive; metastatic breast cancer; targeted therapies; network meta-analysis; subgroup analysis
Categories
Funding
- Medical Research Council, Methodology Research Panel grant
- [MR/T025166/1]
Ask authors/readers for more resources
This review examines the reporting of evidence for the treatment effects in HER2-positive advanced breast cancer (ABC) patients based on hormone receptor status. The study highlights a lack of reporting on the effectiveness of therapies based on hormone receptor subgroups in the identified randomized controlled trials (RCTs), with only a minority reporting progression-free survival. The analysis suggests that future trials in ABC should include reporting on the effects of cancer therapies in hormone receptor subgroups for all outcomes.
Breast cancer is the fifth leading cause of cancer-related deaths worldwide. The randomized controlled trials (RCTs) of targeted therapies in human epidermal receptor 2 (HER2)-positive advanced breast cancer (ABC) have provided an evidence base for regulatory and reimbursement agencies to appraise the use of cancer therapies in clinical practice. However, a subset of these patients harbor additional biomarkers, for example, a positive hormone receptor status that may be more amenable to therapy and improve overall survival (OS). This review seeks to explore the reporting of evidence for treatment effects by the hormone receptor status using the RCT evidence of targeted therapies for HER2-positive ABC patients. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed to identify published RCTs. Extracted data were synthesized using network meta-analysis to obtain the relative effects of HER2-positive-targeted therapies. We identified a gap in the reporting of the effectiveness of therapies by the hormone receptor status as only 15 out of 42 identified RCTs reported hormone receptor subgroup analyses; the majority of which reported progression-free survival but not OS or the overall response rate. In conclusion, we recommend that future trials in ABC should report the effect of cancer therapies in hormone receptor subgroups for all outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available